Delcath Systems, Inc. (DCTH)

NCM – Real vaqt narxi. Valyuta: USD

11.34

+0.28 (2.53%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New York, NY. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and.

08.05.2026

Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript

07.05.2026

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.

07.05.2026

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Total revenue of $25.0 million, compared with $19.8 million in the first quarter of 2025 HEPZATO KIT™ revenue of $23.3 million, compared to $18.0 million in the first quarter of 2025 CHE.

07.05.2026

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective analysis by independent investigators on percutaneous hepatic perfusion with melphalan (M-PHP) using the CHEMOSAT® Hepatic Delivery System was presented today at the ESMO Breast Cancer Congress 2026. Presentation details Congress: ESMO Breast Cancer Congress 2026 Dat.

23.04.2026

Delcath Systems to Host First Quarter 2026 Earnings Call

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 7, 2026 Time.

06.04.2026

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included as a recommended liver-directed regional therapy option in the newly published Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up (April 2026). M-PHP is also re.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Delcath Systems, Inc. (DCTH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Delcath Systems, Inc. (DCTH)

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Videolar

No Data

Press-relizlar

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Videolar

No Data

Press-relizlar

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Search stocks

Delcath Systems, Inc. (DCTH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Delcath Systems, Inc. (DCTH)

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Videolar

No Data

Press-relizlar

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Videolar

No Data

Press-relizlar

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting